Zoetis forecasts 2026 profit and revenue above estimates on strong pet medicine demand
Zoetis expects 2026 earnings to beat estimates behind steady pet medicine demand. Shares rose today as global growth offset softer trends in the United States.
Insights:
Zoetis Inc. announced on February 12, 2026, that it expects its 2026 adjusted earnings to range between $7.00 and $7.10 per share, with total revenue forecasted between $9.83 billion and $10.03 billion. Both figures surpassed Wall Street estimates, providing a significant boost to investor confidence. The company also reported that its quarterly results topped forecasts, a development that pushed shares 4.4% higher in premarket trading.
The company attributed the stronger outlook to steady demand within its companion-animal segment and the resilience of its international markets. These growth drivers are anticipated to offset softer trends currently seen in the US 
US. The updated guidance effectively addresses the low investor expectations that had been cited by market observers prior to the announcement, marking a significant company-level milestone.
US. The updated guidance effectively addresses the low investor expectations that had been cited by market observers prior to the announcement, marking a significant company-level milestone.
